GLAXOSMITHKLINE'S ARRANON APPROVED BY FDA

A A

GlaxoSmithKline reported that the FDA has approved its Arranon chemotherapy for hard-to-treat cancers of the blood and immune system. The company said the FDA approved the injectable drug to treat T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma in patients where at least two standard treatments have already failed. The two cancers affect the blood and bone marrow, and the immune system, respectively, and are characterized by underdeveloped and malfunctioning white blood cells.

The company submitted data showing that 21 percent of adults and 23 percent of children given the treatment responded or achieved remission at least long enough to allow for a stem cell transplant.